|
1
|
Gelb DJ, Oliver E and Gilman S: Diagnostic
criteria for Parkinson's disease. Arch Neurol. 56:33–39.
1999.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Havelund JF, Heegaard NHH, Færgeman NJK
and Gramsbergen JB: Biomarker research in Parkinson's disease using
metabolite profiling. Metabolites. 7(42)2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Dubbioso R, Manganelli F, Siebner HR and
Di Lazzaro V: Fast intracortical sensory-motor integration: A
window into the pathophysiology of Parkinson's disease. Front Hum
Neurosci. 13(111)2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Emamzadeh FN and Surguchov A: Parkinson's
disease: Biomarkers, treatment, and risk factors. Front Neurosci.
12(612)2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Fearnley JM and Lees AJ: Aging and
Parkinson's disease: Substantia nigra regional selectivity. Brain.
114:2283–2301. 1991.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chaudhuri KR, Healy DG and Schapira AH:
Non-motor symptoms of Parkinson's disease: Diagnosis and
management. Lancet Neurol. 5:235–245. 2006.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Barone P: Neurotransmission in Parkinson's
disease: Beyond dopamine. Eur J Neurol. 17:364–376. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kaur R, Mehan S and Singh S: Understanding
multifactorial architecture of Parkinson's disease: Pathophysiology
to management. Neurol Sci. 40:13–23. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Papacocea T, Popa E, Dana T and Papacocea
R: The usefulness of dexamethasone in the treatment of chronic
subdural hematomas. Farmacia. 67:140–145. 2019.
|
|
10
|
Marsili L, Rizzo G and Colosimo C:
Diagnostic criteria for Parkinson's disease: From James Parkinson
to the concept of prodromal disease. Front Neurol.
9(156)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Felicio AC, Shih MC, Godeiro-Junior C,
Andrade LA, Bressan RA and Ferraz HB: Molecular imaging studies in
Parkinson's disease: Reducing diagnostic uncertainty. Neurologist.
15:6–16. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Rizzo G, Copetti M, Arcuti S, Martino D,
Fontana A and Logroscino G: Accuracy of clinical diagnosis of
Parkinson's disease: A systematic review and meta-analysis.
Neurology. 86:566–576. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shao Y and Le W: Recent advances and
perspectives of metabolomics-based investigations in Parkinson's
disease. Mol Neurodegener. 14(3)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Larsen JP, Dupont E and Tandberg E:
Clinical diagnosis of Parkinson's disease. Proposal of diagnostic
subgroups classified at different levels of confidence. Acta Neurol
Scand. 89:242–251. 1994.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Papacocea T, Buraga I, Papacocea R,
Badarau AI, Buraga M, Ciornei C and Adam D: Antioxidant
enzymes-potential targets in intracerebral haemorrhage. Farmacia.
62:1118–1125. 2014.
|
|
16
|
Goldstein DS, Holmes C and Sharabi Y:
Cerebrospinal fluid biomarkers of central catecholamine deficiency
in Parkinson's disease and other synucleinopathies. Brain.
135:1900–1913. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cheng FC, Kuo JS, Chia LG and Dryhurst G:
Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced
homovanillic acid in cerebrospinal fluid: Possible markers for and
potential insights into the pathoetiology of Parkinson's disease. J
Neural Transm (Vienna). 103:433–446. 1996.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Parnetti L, Gaetani L, Eusebi P, Paciotti
S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K and Calabresi P:
CSF and blood biomarkers for Parkinson's disease. Lancet Neurol.
18:573–586. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Eusebi P, Giannandrea D, Biscetti L,
Abraha I, Chiasserini D, Orso M, Calabresi P and Parnetti L:
Diagnostic utility of cerebrospinal fluid α-synuclein in
Parkinson's disease: A systematic review and meta-analysis. Mov
Disord. 32:1389–1400. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gao L, Tang H, Nie K, Wang L, Zhao J, Gan
R, Huang J, Zhu R, Feng S, Duan Z, et al: Cerebrospinal fluid
alpha-synuclein as a biomarker for Parkinson's disease diagnosis: A
systematic review and meta-analysis. Int J Neurosci. 125:645–654.
2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Majbour NK, Vaikath NN, van Dijk KD, Ardah
MT, Varghese S, Vesterager LB, Montezinho LP, Poole S,
Safieh-Garabedian B, Tokuda T, et al: Oligomeric and phosphorylated
alpha-synuclein as potential CSF biomarkers for Parkinson's
disease. Mol Neurodegener. 11(7)2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Parnetti L, Chiasserini D, Persichetti E,
Eusebi P, Varghese S, Qureshi MM, Dardis A, Deganuto M, De Carlo C,
Castrioto A, et al: Cerebrospinal fluid lysosomal enzymes and
alpha-synuclein in Parkinson's disease. Mov Disord. 29:1019–1027.
2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mollenhauer B, Caspell-Garcia CJ, Coffey
CS, Taylor P, Shaw LM, Trojanowski JQ, Singleton A, Frasier M,
Marek K and Galasko D: Longitudinal CSF biomarkers in patients with
early Parkinson disease and healthy controls. Neurology.
19:1959–1969. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mollenhauer B, Zimmermann J, Sixel-Döring
F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Trautmann
E, Zetterberg H, et al: Monitoring of 30 marker candidates in early
Parkinson disease as progression markers. Neurology. 2:168–177.
2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hassan Q, Li SP, Ferrag C and Kerman K:
Electrochemical biosensors for the detection and study of
α-synuclein related to Parkinson's disease- A review. Anal Chim
Acta. 1089:32–39. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Magdalinou NK, Paterson RW, Schott JM, Fox
NC, Mummery C, Blennow K, Bhatia K, Morris HR, Giunti P, Warner TT,
et al: A panel of nine cerebrospinal fluid biomarkers may identify
patients with atypical parkinsonian syndromes. J Neurol Neurosurg
Psychiatry. 86:1240–1247. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hansson O, Janelidze S, Hall S, Magdalinou
N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren L,
Constantinescu R, et al: Blood-based NfL: A biomarker for
differential diagnosis of parkinsonian disorder. Neurology.
88:930–937. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ascherio A, LeWitt PA, Xu K, Eberly S,
Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB,
et al: Urate as a predictor of the rate of clinical decline in
Parkinson's disease. Arch Neurol. 66:1460–1468. 2009.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tohgi H, Abe T, Takahashi S and Kikuchi T:
The urate and xanthine concentrations in the cerebrospinal fluid in
patients with vascular dementia of the Binswanger type, Alzheimer
type dementia, and Parkinson's disease. J Neural Transm Park Dis
Dement Sect. 6:119–126. 1993.PubMed/NCBI View Article : Google Scholar
|
|
30
|
LeWitt P, Schultz L, Auinger P and Lu M:
Parkinson Study Group DATATOP Investigators. CSF xanthine,
homovanillic acid, and their ratio as biomarkers of Parkinson's
disease. Brain Res. 1408:88–97. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Amorini AM, Petzold A, Tavazzi B,
Eikelenboom J, Keir G, Belli A, Giovannoni G, Di Pietro V, Polman
C, D'Urso S, et al: Increase of uric acid and purine compounds in
biological fluids of multiple sclerosis patients. Clin Biochem.
42:1001–1006. 2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Stover JF, Lowitzsch K and Kempski OS:
Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may
reflect glutamate-mediated excitotoxicity in different neurological
diseases. Neurosci Lett. 28:25–28. 1997.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Parkinson Study Group SURE-PD
Investigators. Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME,
Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, et al:
Inosine to increase serum and cerebrospinal fluid urate in
Parkinson's disease: A randomized clinical trial. JAMA Neurol.
71:141–150. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Shen L and Ji HF: Low uric acid levels in
patients with Parkinson's disease: Evidence from meta-analysis. BMJ
Open. 3(e003620)2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Cipriani S, Chen X and Schwarzschild MA:
Urate: A novel biomarker of Parkinson's disease risk, diagnosis and
prognosis. Biomark Med. 4:701–712. 2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Schwarzschild MA, Schwid SR, Marek K,
Watts A, Lang AE, Oakes D, Shoulson I and Ascherio A: Parkinson
Study Group PRECEPT Investigators. Hyson C, et al: Serum urate as a
predictor of clinical and radiographic progression in Parkinson's
disease. Arch Neurol. 65:716–723. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Saito Y: Oxidized DJ-1 as a possible
biomarker of Parkinson's disease. J Clin Biochem Nutr. 54:138–144.
2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Sonuç Karaboğa MN and Sezgintürk MK: A
nano-composite based regenerative neuro biosensor sensitive to
Parkinsonism-associated protein DJ-1/Park7 in cerebrospinal fluid
and saliva. Bioelectrochem. 138(107734)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Carvalho JHS, Brazaca LC, Vieira NCS and
Janegitz BC: Flexible platinum electrodes as electrochemical sensor
and immunosensor for Parkinson's disease biomarkers. Biosens
Bioelectron. 152(112016)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Barbour R, Kling K, Anderson JP, Banducci
K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P and
Chilcote TJ: Red blood cells are the major source of
alpha-synuclein in blood. Neurodegener Dis. 5:55–59.
2008.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Williams SM, Schulz P and Sierks MR:
Oligomeric α-synuclein and β-amyloid variants as potential
biomarkers for Parkinson's and Alzheimer's diseases. Eur J
Neurosci. 43:3–16. 2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Daniele S, Frosini D, Pietrobono D,
Petrozzi L, Lo Gerfo A, Baldacci F, Fusi J, Giacomelli C, Siciliano
G, Trincavelli ML, et al: α-Synuclein heterocomplexes with
β-amyloid are increased in red blood cells of Parkinson's disease
patients and correlate with disease severity. Front Mol Neurosci.
11(53)2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Havelund JF, Andersen AD, Binzer M,
Blaabjerg M, Heegaard NHH, Stenager E, Faergeman NJ and Gramsbergen
JB: Changes in kynurenine pathway metabolism in Parkinson patients
with L-DOPA-induced dyskinesia. J Neurochem. 142:756–766.
2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Chang KH, Cheng ML, Tang HY, Huang CY, Wu
YR and Chen CM: Alternations of metabolic profile and kynurenine
metabolism in the plasma of Parkinson's disease. Mol Neurobiol.
55:6319–6328. 2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Fiandaca MS, Gross TJ, Johnson TM, Hu MT,
Evetts S, Wade-Martins R, Merchant-Borna K, Bazarian J, Cheema AK,
Mapstone M and Federoff HJ: Potential metabolomic linkage in blood
between Parkinson's disease and traumatic brain injury.
Metabolites. 8(50)2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Rodriguez MC, Obeso JA and Olanow CW:
Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease:
A target for neuroprotection. Ann Neurol. 44 (3 Suppl 1):S175–S188.
1998.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Nagesh Babu G, Gupta M, Paliwal VK, Singh
S, Chatterji T and Roy R: Serum metabolomics study in a group of
Parkinson's disease patients from northern India. Clin Chim Acta.
480:214–219. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Stoessel D, Stellmann JP, Willing A,
Behrens B, Rosenkranz SC, Hodecker SC, Stürner KH, Reinhardt S,
Fleischer S, Deuschle C, et al: Metabolomic profiles for primary
progressive multiple sclerosis stratification and disease course
monitoring. Front Hum Neurosci. 12(226)2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Papacocea T, Roşca T, Bădărău A, Papacocea
R, Ciornei C and Ion AD: Cystic meningioma. Chirurgia (Bucur).
104:99–103. 2009.PubMed/NCBI(In Romanian).
|
|
50
|
Hirayama M, Nakamura T, Watanabe H, Uchida
K, Hama T, Hara T, Niimi Y, Ito M, Ohno K and Sobue G:
Urinary8-hydroxydeoxyguanosine correlate with hallucinations rather
than motor symptoms in Parkinson's disease. Parkinsonism Relat
Disord. 17:46–49. 2011.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Bolner A, Pilleri M, De Riva V and Nordera
GP: Plasma and urinary HPLC-ED determination of the ratio of
8-OHdG/2-dG in Parkinson's disease. Clin Lab. 57:859–866.
2011.PubMed/NCBI
|
|
52
|
Sato S, Mizuno Y and Hattori N: Urinary
8-hydroxydeoxy-guanosine levels as a biomarker for progression of
Parkinson disease. Neurology. 64:1081–1083. 2005.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Luan H, Liu LF, Tang Z, Mok VC, Li M and
Cai Z: Elevated excretion of biopyrrin as a new marker for
idiopathic Parkinson's disease. Parkinsonism Relat Disord.
21:1371–1372. 2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Mulak A and Bonaz B: Brain-gut-microbiota
axis in Parkinson's disease. World J Gastroenterol. 21:10609–10620.
2015.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Zierer J, Jackson MA, Kastenmüller G,
Mangino M, Long T, Telenti A, Mohney RP, Small KS, Bell JT, Steves
CJ, et al: The fecal metabolome as a functional readout of the gut
microbiome. Nat Genet. 50:790–795. 2018.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Unger MM, Spiegel J, Dillmann KU,
Grundmann D, Philippeit H, Bürmann J, Faßbender K, Schwiertz A and
Schafer KH: Short chain fatty acids and gut microbiota differ
between patients with Parkinson's disease and age-matched controls.
Parkinsonism Relat Disord. 32:66–72. 2016.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Boeve BF: Idiopathic REM sleep behaviour
disorder in the development of Parkinson's disease. Lancet Neurol.
12:469–482. 2013.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Papacocea IR, Badarau IA, Ciornei MC,
Burciulescu SL and Papacocea T: The effects of caffeine intake on
cardiovascular parameters in sleep deprived medical residents. Rev
Chim. 70:1445–1448. 2019.
|
|
59
|
Global Parkinson's Disease Survey (GPDS)
Steering Committee. Factors impacting on quality of life in
Parkinson's disease: Results from an international survey. Mov
Disord. 17:60–67. 2002.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Schrag A, Jahanshahi M and Quinn N: What
contributes to quality of life in patients with Parkinson's
disease? J Neurol Neurosurg Psychiatry. 69:308–312. 2000.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Ciobanu AM, Roşca T, Vlădescu CT, Tihoan
C, Popa MC, Boer MC and Cergan R: Frontal epidural empyema (Pott's
puffy tumor) associated with Mycoplasma and depression. Rom J
Morphol Embryol. 55 (Suppl 3):S1203–S1207. 2014.PubMed/NCBI
|
|
62
|
Goodarzi Z, Mrklas KJ, Roberts DJ, Jette
N, Pringsheim T and Holroyd-Leduc J: Detecting depression in
Parkinson's disease: A systematic review and meta-analysis.
Neurology. 87:426–437. 2016.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Remy P, Doder M, Lees A, Turjanski N and
Brooks D: Depression in Parkinson's disease: Loss of dopamine and
noradrenaline innervation in the limbic system. Brain.
128:1314–1322. 2005.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Tong Q, Zhang L, Yuan Y, Jiang S, Zhang R,
Xu Q, Ding J, Li D, Zhou X and Zhang K: Reduced plasma serotonin
and 5-hydroxyindoleacetic acid levels in Parkinson's disease are
associated with nonmotor symptoms. Parkinsonism Relat Disord.
21:882–887. 2015.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Dong MX, Feng X, Xu XM, Hu L, Liu Y, Jia
SY, Li B, Chen W and Wei YD: Integrated analysis reveals altered
lipid and glucose metabolism and identifies NOTCH2 as a biomarker
for Parkinson's disease related depression. Front Mol Neurosci.
31:1–18. 2018.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Akbaraly TN, Kumari M, Head J, Ritchie K,
Ancelin ML, Tabák AG, Brunner E, Chaudieu I, Marmot MG, Ferrie JE,
et al: Glycemia, insulin resistance, insulin secretion, and risk of
depressive symptoms in middle age. Diabetes Care. 36:928–934.
2013.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Oh J and Kim TS: Serum lipid levels in
depression and suicidality: The Korea National Health and Nutrition
Examination Survey (KNHANES) 2014. J Affect Disord. 213:51–58.
2017.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Dong J, Beard JD, Umbach DM, Park Y, Huang
X, Blair A, Kamel F and Chen H: Dietary fat intake and risk for
Parkinson's disease. Mov Disord. 29:1623–1630. 2014.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Kanno T, Tanaka A and Nishizaki T:
Linoleic acid derivative DCP-LA ameliorates stress-induced
depression-related behavior by promoting cell surface 5-HT1A
receptor translocation, stimulating serotonin release, and
inactivating GSK-3β. Mol Neurobiol. 51:523–532. 2015.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Fleminger S: Left-sided Parkinson's
disease is associated with greater anxiety and depression. Psychol
Med. 21:629–638. 1991.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Singh A, Althoff R, Martineau J and
Jacobson J: Pramipexole, ropinirole, and mania in Parkinson's
disease. Am J Psychiatry. 162:814–815. 2005.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Kipps CM, Fung VSC, Grattan-Smith P, de
Moore GM and Morris JGL: Movement disorder emergencies. Mov Disord.
20:322–334. 2005.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Aarsland D, Larsen JP, Tandberg E and
Laake K: Predictors of nursing home placement in Parkinson's
disease: A population-based, prospective study. J Am Geriatr Soc.
48:938–942. 2000.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Diederich NJ, Goetz CG and Stebbins GT:
Repeated visual hallucinations in Parkinson's disease as disturbed
external/internal perceptions: Focused review and a new integrative
model. Mov Disord. 20:130–140. 2005.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Fénelon G, Mahieux F, Huon R and Ziégler
M: Hallucinations in Parkinson's disease: Prevalence,
phenomenology, and risk factors. Brain. 123:733–734.
2000.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Eversfield CL and Orton LD: Auditory and
visual hallucination prevalence in Parkinson's disease and dementia
with Lewy bodies: A systematic review and meta-analysis. Psychol
Med. 49:2342–2353. 2019.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Emre M: Dementia associated with
Parkinson's disease. Lancet Neurol. 2:229–237. 2003.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Laakso MP, Partanen K, Riekkinen P,
Lehtovirta M, Helkala EL, Hallikainen M, Hanninen T, Vainio P and
Soininen H: Hippocampal volumes in Alzheimer's disease, Parkinson's
disease with or without dementia: An MRI study. Neurology.
46:678–681. 1996.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Ibarretxe-Bilbao N, Tolosa E, Junque C and
Marti MJ: MRI and cognitive impairment in Parkinson's disease. Mov
Disord. 24 (Suppl 2):S748–S753. 2009.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Bouchard TP, Malykhin N, Martin WR,
Hanstock CC, Emery DJ, Fisher NJ and Camicioli RM: Age and
dementia-associated atrophy predominates in the hippocampal head
and amygdala in Parkinson's disease. Neurobiol Aging. 29:1027–1039.
2008.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Kenny ER, Burton EJ and O'Brien JT: A
volumetric magnetic resonance imaging study of entorhinal cortex
volume in dementia with Lewy bodies. A comparison with Alzheimer's
disease and Parkinson's disease with and without dementia. Dement
Geriatr Cogn Disord. 26:218–225. 2008.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Burton EJ, McKeith IG, Burn DJ and O'Brien
JT: Brain atrophy rates in Parkinson's disease with and without
dementia using serial magnetic resonance imaging. Mov Disord.
20:1571–1576. 2005.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Bohnen NI, Kaufer DI, Ivanco LS, Lopresti
B, Koeppe RA, Davis JG, Mathis CA, Moore RY and DeKosky ST:
Cortical cholinergic function is more severely affected in
parkinsonian dementia than in Alzheimer disease: An in vivo
positron emission tomographic study. Arch Neurol. 60:1745–1748.
2003.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Lange KW, Kornhuber J and Riederer P:
Dopamine/glutamate interactions in Parkinson's disease. Neurosci
Biobehav Rev. 21:393–400. 1997.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Bonnet AM: Involvement of non-dopaminergic
pathways in Parkinson's disease: Pathophysiology and therapeutic
implications. CNS Drugs. 13:351–364. 2000.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Romosan AM, Dehelean L, Romosan RS, Andor
M, Bredicean AC and Simu MA: Affective theory of mind in
Parkinson's disease: The effect of cognitive performance.
Neuropsychiatr Dis Treat. 15:2521–2535. 2019.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Alves G, Lange J, Blennow K, Zetterberg H,
Andreasson U, Førland MG, Tysnes OB, Larsen JP and Pedersen KF: CSF
Aβ42 predicts early-onset dementia in Parkinson's disease.
Neurology. 82:1784–1790. 2014.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Hall S, Öhrfelt A, Constantinescu R,
Andreasson U, Surova Y, Bostrom F, Nilsson C, Håkan W, Decraemer H,
Någga K, et al: Accuracy of a panel of 5 cerebrospinal fluid
biomarkers in the differential diagnosis of patients with dementia
and/or parkinsonian disorders. Arch Neurol. 69:1445–1452.
2012.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Andersson M, Zetterberg H, Minthon L,
Blennow K and Londos E: The cognitive profile and CSF biomarkers in
dementia with Lewy bodies and Parkinson's disease dementia. Int J
Geriatr Psychiatry. 26:100–105. 2011.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Özgür E, Uyanık HU, Senel S and Uzun L:
Immunoaffinity biosensor for neurofilament light chain detection
and its use in Parkinson's diagnosis. Mater Sci Eng B.
256(114545)2020.
|
|
91
|
Scalzo P, Kümmer A, Bretas TL, Cardoso F
and Teixeira AL: Serum levels of brain-derived neurotrophic factor
correlate with motor impairment in Parkinson's disease. J Neurol.
257:540–545. 2010.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Bernhard FP, Heinzel S, Binder G, Weber K,
Apel A, Roeben B, Deuschle C, Maechtel M, Heger T, Nussbaum S, et
al: Insulin-like growth factor 1 (IGF-1) in Parkinson's disease:
Potential as trait-, progression- and prediction marker and
confounding factors. PLoS One. 11(e0150552)2016.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Shen Z, Huang J, Wei H, Niu H, Li B, Li R
and Liu G: Validation of an in vivo electrochemical immunosensing
platform for simultaneous detection of multiple cytokines in
Parkinson's disease mice model. Bioelectrochem.
134(107532)2020.PubMed/NCBI View Article : Google Scholar
|
|
94
|
More SV, Kumar H, Kim IS, Song SY and Choi
DK: Cellular and molecular mediators of neuroinflammation in the
pathogenesis of Parkinson's disease. Mediators Inflamm.
2013(952375)2013.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Yu SY, Zuo LJ, Wang F, Chen ZJ, Hu Y, Wang
YJ, Wang XM and Zhang W: Potential biomarkers relating pathological
proteins, neuroinflammatory factors and free radicals in PD
patients with cognitive impairment: A cross-sectional study. BMC
Neurol. 14:113–119. 2014.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Biomarkers Definitions Working Group.
Biomarkers and surrogate endpoints: Preferred definitions and
conceptual framework. Clin Pharmacol Ther. 69:89–95.
2001.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Rabinca AA, Buleandra M, Tache F,
Mihailciuc C, Ciobanu AM, Stefanescu DC and Ciucu AA: Voltammetric
method for simultaneous determination of L-Dopa and benserazide.
Curr Anal Chem. 13:218–224. 2017.
|
|
98
|
Patrascu DG, David V, Balan I, Ciobanu A,
David I G, Lazar P, Ciurea I, Stamatin I and Ciucu AA: Selective
DPV method of dopamine determination in biological samples
containing ascorbic acid. Anal Lett. 43:1100–1110. 2010.
|
